Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +971 (0) 4 368 1644
  • GDPR
  • Journalists
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +971 (0) 4 368 1644 from 8 AM - 5:30 PM GMT

    • Contact
    • Contact

      +971 (0) 4 368 1644
      from 8 AM - 5:30 PM GMT

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

The Lancet: Excellent Efficacy of Hisun's Favipiravir Against COVID-19 in Turkey
  • USA - English


News provided by

Zhejiang Hisun Pharmaceutical Co.,Ltd.

26 Aug, 2020, 13:55 GMT

Share this article

Share toX

Share this article

Share toX

TAIZHOU, China, Aug. 26, 2020 /PRNewswire/ -- Recently, Preprints with The Lancet has published a preliminary study report on Turkey's using Favipiravir produced by Hisun to treat COVID-19. The report says after Favipiravir was used in hospitals across Turkey for five days, the overall ICU patient admission rate in the country was reduced by half and that for patients under 60 years old dropped from nearly 20% to 6.6%, with a significant decline in the intubation rate (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3622357).

Continue Reading
Hisun Favipiravir Batter Against COVID-19
Hisun Favipiravir Batter Against COVID-19

The Turkish Government has taken a series of preventive measures since the outbreak of COVID-19 in early January. Later on March 25, it incorporated Favipiravir into the COVID-19 treatment scheme and sent one million Favipiravir tablets purchased from Hisun to hospitals all over the country for the free treatment of COVID-19 patients. Turkey's Health Minister Fahrettin Koca said, with the early use of Favipiravir in Turkey, the pneumonia rate sees a gradual decline and that in Ankara, the capital of Turkey, has dropped from 12.1% to 5.61% (https://anadoludabugun.com.tr/turkiye/saglik-bakani-koca-evde-tedavide-yeni-bir-uygulamaya-geciyoruz-122238h).

Now the pandemic continues to worsen worldwide, a number of asymptomatic patients pose the greatest challenge for the battle against the disease in the world. For about 10-15% mild or moderate cases, the infection will spread to the lungs. When that happens, the disease can snowball from moderate to severe "very, very quickly," said Bruce Aylward, an assistant director-general with the World Health Organization (https://www.michigansthumb.com/science/article/How-a-mild-case-of-COVID-19-can-turn-deadly-15123209.php). Therefore,the early diagnosis and treatment of asymptomatic patients or those with mild symptoms is extremely important.

Favipiravir produced by Hisun has been recommended by a good many countries for treating COVID-19 and has already been used to support over 20 countries and regions in battling the disease (https://irannewsgazette.com/about-us/).

Contact person:
Ms. Li
Email: [email protected]
Tel: +86-137-180-259-66

Website: http://www.hisunpharm.com/en/favipiravir.php
YouTube: https://youtu.be/2sTb1AEXLWU

Related Links

http://www.hisunpharm.com

Modal title

Contact PR Newswire

  • +971 (0) 4 368 1644
    from 8 AM - 5:30 PM GMT

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+971 (0) 4 368 1644
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.